Pharma Giant Breaks Silence on Cancer Drug Trial Data Discrepancy

  • Merck recently disclosed results from a Phase 3 trial for Keytruda without issuing a press release or academic paper.
  • The trial involved more than 500 lung cancer patients using an injectable form of Keytruda.
  • Analysts at Shinhan Securities noticed the trial data and reported a 18.4% increase in death risk for subcutaneous Keytruda users.
  • Merck’s spokesman stated that mortality rates were similar, but didn’t provide more details.
  • The company is focusing on an injectable Keytruda combined with an enzyme for potential release later this year.
  • Keytruda sales accounted for 40% of Merck’s total revenue in 2023.

Merck has typically publicized results from its Keytruda trials, but recently disclosed data in a federal database without an announcement. The trial compared injectable and intravenous forms of the cancer drug. Analysts spotted the data and reported a higher death risk for the subcutaneous version, while Merck only confirmed similar mortality rates. The company is now focusing on a combined Keytruda enzyme treatment.

Factuality Level: 8
Factuality Justification: The article provides accurate and objective information about Merck’s Phase 3 trial results for a new injectable form of Keytruda, discussing the company’s plans for the drug, its sales, and the potential impact on the market. It also mentions the differences in mortality rates between the subcutaneous and intravenous versions of the drug, as well as the company’s focus on developing a subcutaneous formulation. The article cites sources and provides context about Merck’s history with Keytruda trials and its importance to the company’s revenue.
Noise Level: 3
Noise Justification: The article provides relevant information about Merck’s Phase 3 trial results for a new injectable form of Keytruda and discusses its potential impact on the company’s revenue. However, it includes some repetitive information and could benefit from more in-depth analysis or expert opinions.
Public Companies: Merck (MERCK)
Key People: Dr. Dean Li (President of Merck Research Laboratories), Louise Chen (Analyst at Cantor Fitzgerald)

Track all markets on TradingView

Financial Relevance: Yes
Financial Markets Impacted: Merck shares, Pfizer, Bristol Myers Squibb
Financial Rating Justification: The article discusses Merck’s financial performance and its drug Keytruda’s sales, as well as the potential impact on competitors Pfizer and Bristol Myers Squibb due to the development of a new injectable form of Keytruda. It also mentions the stock performance of these companies.
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Extreme Rating Justification: There is no extreme event mentioned in the article.

Reported publicly: www.marketwatch.com